Special Issue

Antibiotic Targets in Bacterial DNA Replication and Cell Division

Message from the Guest Editors

This issue of Antibiotics is dedicated to the topics of Bacterial DNA Replication and Cell Division and Inhibitors of these processes. Following replication initiation, for most bacteria governed by the DnaA protein, replication of the bacterial chromosome is carried out by a multi-protein complex called the replisome, which is present in only few copies per cell. The proteins involved in DNA replication should provide an attractive target for antimicrobial inhibition and vet only antibiotics that indirectly target the replication process are in clinical use. These inhibit the type-II topoisomerases that relieve topological stress created by DNA unwinding and decatenate daughter chromosomes prior to cell division. This Special Issue summarizes current knowledge of bacterial DNA replication and cell division, and their inhibition by antimicrobials. It is our pleasure to invite submissions of high quality primary research manuscripts and review articles addressing the molecular mechanisms of bacterial DNA replication and cell division, their coordination and regulation, and their inhibition by established drugs and novel compounds.

Guest Editors

Prof. Dr. Anders Løbner-Olesen

Prof. Dr. Nicholas Dixon

Prof. Dr. Elizabeth Harry

Deadline for manuscript submissions closed (31 August 2020)



an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 7.3 Indexed in PubMed



mdpi.com/si/19209

Antibiotics MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 7.3 Indexed in PubMed



antibiotics



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)